In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report), with a price target of $2.00. The company’s shares opened today at $0.83.
White covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, Inozyme Pharma, and Bolt Biotherapeutics. According to TipRanks, White has an average return of -17.8% and a 25.49% success rate on recommended stocks.
SAB Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $2.50.
See today’s best-performing stocks on TipRanks >>
Based on SAB Biotherapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $581.1 thousand and a GAAP net loss of $7.35 million. In comparison, last year the company earned a revenue of $11.8 million and had a net profit of $985.86 thousand
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
Read More on SABS:
